Biochemical assessment of Paget's disease of bone

Journal of Bone and Mineral Research

Volumn 22, Issue SUPPL. 2, 2007, Pages

  Shankar, Subramanian ^a   Hosking, David J ^b  

^a Command Hospital ^*  (India)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Bone turnover markers; Critical difference response; Paget's disease

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN; PAMIDRONIC ACID; PROCOLLAGEN; PYRIDINOLINE; BIOLOGICAL MARKER; PEPTIDE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CROSS LINKING; DISEASE ACTIVITY; HUMAN; OSTEOLYSIS; PAGET BONE DISEASE; TREATMENT RESPONSE; BONE REMODELING; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE REMODELING; HUMANS; OSTEITIS DEFORMANS; OSTEOCALCIN; PEPTIDES;

EID: 34247851110     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.06S204     Document Type: Article

References (26)

1. Meunier PJ, Saison C, Mathieu L, Chapuy MC, Delmas P, Alexandre C, Charhon S 1987 Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop Rel Res 217:37-44.
2. Nagant De Deuxchaissnes C, Krane SM 1964 Paget's disease of bone: Clinical and metabolic observations. Medicine (Baltimore) 43:233-266.
3. Coulton LA, Preston CJ, Couch M, Kanis JA 1988 An evaluation of serum osteocalcin in Paget's disease of bone and its response to diphosphonate treatment. Arthritis Rheum 31:1142-1147.
4. Randall AG, Kent GN, Garcia-Webb P, Bhagat CI, Pearce DJ, Gutteridge DH, Prince RL, Stewart G, Stuckey B, Will RK, Retallack RW, Price RI, Ward L 1996 Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. J Bone Miner Res 11:1176-1184.
5. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T 2004 Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 35:224-230.
6. Srivastava AK, Mohan S, Singer FR, Baylink DJ 2002 A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. Bone 31:62-69.
7. Ingram RT, Collazo-Clavell M, Tiegs R, Fitzpatrick LA 1996 Paget's disease is associated with changes in the immunohistochemical distribution of noncollagenous matrix proteins in bone. J Clin Endocrinol Metab 81:1810-1820.
8. Delmas PD 1999 Biochemical markers of bone turnover in Paget's disease of bone. J Bone Miner Res 14:S2;66-69.
9. Morrison NA, Shine J, Fragonas JC, Verkest V, McMenemy ML, Eisman JA 1989 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 246:1158-1161.
10. Papapoulos SE, Frolich M, Mudde AH, Harinck HI, vd Berg H, Bijvoet OL 1987 Serum osteocalcin in Paget's disease of bone: Basal concentrations and response to bisphosphonate treatment. J Clin Endocrinol Metab 65:89-94.
11. Naylor KE, Jackson B, Eastell R 2003 The renal clearance of free and peptide-bound deoxypyridinoline: Response to pamidronate treatment of Paget's disease. J Bone Miner Res 18:658-661.
12. Garnero P, Fledelius C, Gineyts E, Serre CM, Vignot E, Delmas PD 1997 Decreased beta-isomerization of the C-terminal telopeptide of type 1 collagen alpha 1 chain in Paget's disease of bone. J Bone Miner Res 12:1407-1415.
13. Alexandersen P, Peris P, Guanabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PA 2005 Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 20:588-595.
14. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R 2002 Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886-890.
15. Brady JD, Ju J, Robins SP 1999 Isoaspartyl bond formation within N-terminal sequences of collagen type I: Implications for their use as markers of collagen degradation. Clin Sci (Lond) 96:209-215.
16. Alvarez L, Ricos C, Peris P, Guanbens N, Monegal A, Pons F, Ballesta AM 2000 Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Bone 26:571-576.
17. Blumsohn A, Naylor KE, Assiri AM, Eastell R 1995 Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 41:1592-1598.
18. Alvarez L, Peris P, Pons F, Guanabens N, Herranz R, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Munoz-Gomez J, Ballesta AM 1997 Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Arthritis Rheum 40:461-468.
19. Alvarez L, Guanabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Munoz-Gomez J, Rivera-Fillat F, Ballesta AM 1995 Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 10:458-465.
20. Alvarez L, Guanabens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Munoz-Gomez J, Ballesta AM 2001 Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 29:447-452.
21. Eekhoff ME, Zwinderman AH, Haverkort DM, Cremers SC, Hamdy NA, Papapoulos SE 2003 Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Bone 33:831-838.
22. Gray RE, Yates AJ, Preston CJ, Smith R, Russell RG, Kanis JA 1987 Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med 64:755-767.
23. Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL 1987 Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) 295:1301-1305.
24. Patel S, Stone MD, Coupland C, Hosking DJ 1993 Determinants of remission of Paget's disease of bone. J Bone Miner Res 8:1467-1473.
25. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D 2005 Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353:898-908.
26. Gutteridge DH, Ward LC, Stewart GO, Retallack RW, Will RK, Prince RL, Criddle A, Bhagat CI, Stuckey BG, Price RI, Kent GN, Faulkner DL, Geelhoed E, Gan SK, Vasikaran S 1999 Paget's disease: Acquired resistance to one amino bisphosphonate with retained response to another. J Bone Miner Res 14:S2;79-84.